J&J-Merck team up in Canada, plan for Pepcid AC launch in first half of 1996.
This article was originally published in The Tan Sheet
Executive Summary
NEW J&J-MERCK CANADIAN JOINT VENTURE TARGETS PEPCID AC LAUNCH for the first half on 1996. The nonprescription famotidine will be the first of several potential Rx-to-OTC switch products developed by Merck that are slated for marketing in Canada through the venture. The companies also will contribute a number of their existing OTC brands from their respective Canadian businesses.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning